Tylenol Liver Damage Lawsuits to Be Readied for Early Bellwether Trials, Bernstein Liebhard LLP Reports
New York, New York (PRWEB) November 20, 2014 -- Tylenol lawsuits (http://www.tylenollawsuitcenter.com/) filed on behalf of individuals who allegedly suffered severe liver damage due to the use of the over-the-counter medications continue to move forward in a multidistrict litigation now underway in U.S. District Court, Eastern District of Pennsylvania, Bernstein Liebhard LLP reports. According to a Joint Status Report submitted by the parties on November 14th, case specific discovery is nearly completed in the six Tylenol lawsuits that have been designated as possible bellwether trial candidates. The parties are now in the process of choosing one of those cases for the litigation’s first trial, and have been directed to submit that selection to the Court by December 1st. The first bellwether trial of a Tylenol liver damage case is expected to begin in 2016. (In Re: Tylenol (Acetaminophen) Marketing, Sales Practices and Products Liability Litigation, MDL No. 2436)
“Our Firm has heard from a number of individuals who allegedly suffered severe liver damage due to the acetaminophen in Tylenol products. We look forward to the commencement of bellwether trials in the federal litigation, as they may provide valuable insight into how juries will rule in similar Tylenol lawsuits,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is offering free legal reviews to consumers who were allegedly harmed by a Tylenol-brand over-the-counter medication.
Tylenol Liver Damage Litigation
According to court documents, at least 163 Tylenol liver damage claims are currently pending in the litigation underway in the Eastern District of Pennsylvania. The complaints allege that Johnson & Johnson and McNeil Consumer Healthcare failed to provide consumers with adequate warnings regarding the risks associated with acetaminophen contained in Tylenol-brand medications. In many cases, plaintiffs claim that liver damage caused by Tylenol occurred even though the medication was used in accordance with label directions, and was severe enough to result in hospitalization, liver transplantation, or death.
Recently, an investigation conducted by Consumer Reports found that acetaminophen is now the leading cause of liver injuries in the U.S., and sends more than 80,000 people to the emergency room every year. Among other thing, the report detailed research which suggested that exceeding just 4,000 milligrams of acetaminophen for just a few days can result in serious liver damage and other complications. Yet the daily limits recommended for many over-the-counter acetaminophen products come very close to this threshold.*
In January, the U.S. Food & Drug Administration (FDA) did finalize new guidance for the use of acetaminophen in prescription medications. However, these new guidelines do not apply to over-the-counter medications like Tylenol.** And last month, the agency issued draft guidance regarding over-the-counter liquid pediatric medications that contain acetaminophen. ***
In August 2013, Bloomberg.com reported that over-the-counter Extra Strength Tylenol caplets each contain 500 mg of acetaminophen, well over the limits of 325 mg per tablet mandated by the FDA for prescription medications.****
Victims of acetaminophen-induced liver damage allegedly linked to a Tylenol-brand medication may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. To learn more about filing a Tylenol lawsuit, please visit Bernstein Liebhard LLP’s website. Free, confidential and no-obligation case reviews are available by calling 800-511-5092.
*newsnet5.com/money/consumer/consumer-specialist/warning-about-acetaminophen-consumer-reports-investigates, Consumer Reports (via 5 ABC News) October 29, 2014
**federalregister.gov/articles/2011/01/14/2011-709/prescription-drug-products-containing-acetaminophen-actions-to-reduce-liver-injury-from, Federal Register, January 2014
***fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM417568.pdf, FDA, October 2014
****bloomberg.com/news/2013-08-29/j-j-adds-warning-to-tylenol-caps-on-acetaminophen-risk.html, Bloomberg.com, August 29, 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.tylenollawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author
Felecia L. Stern, Tylenol Lawsuit Information Center, http://www.tylenollawsuitcenter.com/, +1 800-511-5092, [email protected]
Share this article